Anti-PD-1/PD-L1 Antibodies Plus Gemcitabine and Cisplatin for Advanced CCA — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Anti-PD-1/PD-L1 Antibodies Plus Gemcitabine and Cisplatin for Advanced CCA — Stella

Recruiting

Back to Cholangiocarcinoma trials

Trial locations(1 site)

China

Zhongshan Hospital Fudan university, Shanghai, Shanghai Municipality

Key details

Sponsor

Shanghai Zhongshan Hospital

Enrollment target

~50 participants

Started

July 2024

Primary completion

December 2029

Age range

18 Years – 90 Years

Last updated December 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov